SEZARY SYNDROME
Clinical trials for SEZARY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SEZARY SYNDROME trials appear
Sign up with your email to follow new studies for SEZARY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack c…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:42 UTC
-
New drug shows promise for rare skin cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called tulmimetostat (DZR123) in 24 adults with advanced mycosis fungoides or Sezary syndrome, rare types of skin lymphoma. Participants must have already tried at least one prior treatment. The main goals are to check the drug's safety and…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Experimental combo targets Hard-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose, check safety, and see if the combination shrinks tumors. About 38 adults with certai…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Drug combo shows promise for rare skin cancer
Disease control OngoingThis study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can help control advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. It includes 14 adults who have already tried at least one other treatment. T…
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Virus-Immunotherapy combo targets tough skin cancers
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't improved with standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors to help the immune system recognize and attack cancer …
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new treatment called WU-CART-007 for people with certain blood cancers (like acute myeloid leukemia and T-cell lymphoma) that have not responded to standard therapy. The treatment uses donor immune cells that are specially modified to target and kil…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC